Anna Lantz
Affiliated to Research
| Docent
E-mail: anna.lantz.1@ki.se
Visiting address: Nobels väg 12a, 17165 Solna
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Eklund, 171 77 Stockholm
About me
- Anna Lantz (former Wallerstedt)
Associate Professor in Urology at Karolinska Institutet and Consultant
Urologist at Karolinska University Hospital Solna, focusing on detection and
treatment of prostate cancer, combining clinical work with independent
research at Karolinska Institutet.
Anna Lantz defended her thesis "Outcomes after surgical treatment of
localized prostate cancer with focus on urinary incontinence and short term
complications" in March 2015 at Karolinska Institutet. In 2016 to 2018 she
undertook postdoctoral studies at Department of Medical Epidemiology and
Biostatistics within the STHLM-studies with focus on improved detection of
prostate cancer, setting up the STHLM3AS trial as Principal Investigator.
During 2019-2020 Anna Lantz undertook international postdoctoral studies at
Icahn School of Medicine, Mount Sinai Hospital in New York.
2021 - Principal Investigator site 723 EMBARK - MDV3100-13
2018- SLL Postdoc
2011-2016 SLL Research Resident
2011 26th Annual EAU Congress in Vienna, Best Poster Presentation Award
*Research grants*
2020 Åke Wibergs Stiftelse
2020 Karolinska Institutets Research Grant
2020 Svenska sällskapet för medicinsk forskning
2020 Prostatacancerförbundet
2019-2020 Svenska Läkaresällskapets Postdoc
2019 Hirsch resebidrag för kirurger
2018-2019 Postdoc, Stockholm County Council
2017 Grant, Johan Hedins Stiftelse
2011-2016 Research-Resident in Urology, Stockholm County Council
2021 Associate Professor (KI)
2019-2020 Postdoc (Icahn School of Medicine, Mount Sinai Hospital, New York)
2016-2018 Postdoc (Department of Medical Epidemiology and Biostatistics,
KI)
2015 Ph.D. (Department of Molecular Medicine and Surgery, KI)
2008 M.D. (KI)
Research
- *Principal Investigator for Prostate Cancer IRE Study (PRIS) – A
randomized controlled trial comparing focal to radical treatment in localized
prostate cancer*
Radical treatments of localized prostate cancer are associated with a
significant risk for morbidity in terms of incontinence and impotence, while
providing only small survival benefits compared to active surveillance.
Advances in the field of prostate cancer MRI together with the effort to
reduce treatment morbidity has led to development methods for focal treatment
of prostate cancer during the latest decade. Irreversible Electroporation
(IRE) is a novel image-guided tissue ablation technology that induces cell
death through short pulsed electric fields. In comparison to thermal
therapies IRE has the advantage of being non-thermal with elements of tissue
selectivity which significantly reduces toxicity on anatomical structures
surrounding the tumour. The aim of the planned study is to evaluate the
feasibility to treat localized prostate cancer with IRE in comparison with
conventional radical treatments (surgery or radiation) through a randomized
controlled trial with the primary objective to locally control the tumour
with a minimum of side effects. The ethical review board has approved the
study and inclusion started in 2022. The study is now in its randomised
phase.
*Medically responsible for Organised prostate cancer testing (OPT) in Region
Stockholm Gotland*
Prostate cancer is the cancer form with highest mortality rates among men in
Sweden. Research has shown that screening with PSA reduces mortality from the
disease. This has led to widespread unorganized PSA testing that has proven
to be inefficient, unequal and resource intensive. Therefore, in 2018, the
National Board of Health and Welfare (Socialstyrelsen) commissioned Sweden's
municipalities and county councils (SKR) to develop and implement programs
for organized prostate cancer testing (OPT) to improve efficiency and
equality, reduce resource usage, and test supplementary diagnostic tests to
prostate specific antigen (PSA). Region Stockholm Gotland initiated OPT in
2022 by inviting all men 50 y of age to undergo testing (around 17 000
men/year). The OPT program include all steps from invitation to biopsy result
notification. We are currently evaluating the results of the first year of
OPT.
*LAPPRO-trial evaluating functional and oncological outcomes after prostate
cancer surgery*
The overarching aim with my research has been to improve patient care for men
with prostate cancer. The LAPPRO-trial is a multicentre, prospective
controlled trial of men who underwent radical prostatectomy between 2008 and
2011 (n=4003). In this national collaborative study, comprising men from 14
hospitals in Sweden, I have evaluated functional outcomes, such as
incontinence, erectile dysfunction and quality of life after radical
prostatectomy. I defended my thesis presenting data from the LAPPRO trial in
2015 and have continued my collaboration with the group since then. In 2021
the 8-year follow-up of the trial was published in European Urology. We are
currently working on the 12-year follow-up.
*Principal Investigator for STHLM3AS and STHLM3AS-NorDCaP*
The latest years, I have focused on evaluating diagnostics and follow up in
men with low-risk prostate cancer. Specifically, I analyzed men with low-risk
prostate cancer on active surveillance in the STHLM0* *database and found
that the guidelines for monitoring are not followed. We identified the need
for improved active surveillance protocols and thus started the STHLM3-AS
with the aim to improve monitoring of men with low-risk prostate cancer,
including the Stockholm3-test and MRI. The study included over 300 men and
the results, published in JNCI, show that our new proposed protocol leads to
higher detection rate of significant prostate cancer including less invasive
monitoring. To validate our results, we initiated STHLM3AS NorDCaP including
men from Norway, Denmark, Finland and Sweden with the aim to recruit 400 men
on active surveillance within 2021. The objective of the study is
to validate our results from STHLM3AS and improve surveillance for low risk
prostate cancer.
*Studies within the STHLM0 database*
Using the population-based cohort STHLM0, I have been involved in several
studies evaluating the effect of drugs and diseases on the risk of being
diagnosed with prostate cancer. In* *2018 we performed a large
population-based historical prospective study using data from STHLM0 and
found a reduced risk of prostate cancer among 5-ARI users. We are currently
investigating the effect of 5-ARIs on prostate cancer specific mortality.
*Mount Sinai Prostate Cancer Cohort, New York*
In 2019-2020 I was offered a research position at Mount Sinai Hospital in New
York City, USA. During my postdoc at Mount Sinai I evaluated diagnostics in
prostate cancer using MRI and biomarkers, specifically for men with low risk
prostate cancer. In my main publication we created a nomogram for including
men into active surveillance rather than curative treatment, in an attempt to
increase quality of life and decrease overtreatment of men with clinically
insignificant prostate cancer. Our results emphasize that a greater
proportion of men with localized prostate cancer can be treated
conservatively with active surveillance in a safe way if the selection is
optimized. Furthermore, through the collaboration I have been involved in
creating a multicenter MRI-database with data from 5 countries, containing
3700 men with prostate cancer that has underwent MRI and targeted biopsies.
After my postdoc period I have continued to have close contact with my
collegues at Mount Sinai, collaborating in different projects.
Teaching
- *Leadership and pedagogical training*
2019 Teaching and Learning in Higher Education Distance (GHPD) Course
2018-19 Head of urological education, Karolinska University Hospital
2017- Teacher for medical students at the Department of Urology in
Karolinska Hospital
2016-17 Teacher in Research School for clinicians in Epidemiology,
Karolinska Institutet
*Teaching experience*
Around 140 teaching hours at Karolinska University Hospital and Karolinska
Institutet. The teaching has involved lectures, seminars and bed side /OR
teaching.
Articles
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;62:61-67
-
Article: EUROPEAN UROLOGY. 2024;85(3):207-214
-
Article: NEJM EVID. 2023;2(12):evidoa2300251
-
Article: WORLD JOURNAL OF UROLOGY. 2023;41(11):2967-2974
-
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
-
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;58:11-19
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2023;51:89-94
-
Article: WORLD JOURNAL OF UROLOGY. 2023;41(1):85-92
-
Article: EUROPEAN UROLOGY. 2022;82(5):559-568
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;44:69-75
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;41:45-54
-
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
-
Article: BJU INTERNATIONAL. 2022;129(6):695-698
-
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(3):182-190
-
Article: EUROPEAN UROLOGY ONCOLOGY. 2022;5(2):187-194
-
Article: EUROPEAN UROLOGY. 2021;80(5):650-660
-
Article: WORLD JOURNAL OF UROLOGY. 2021;39(9):3239-3249
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;30:25-33
-
Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804
-
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2021;113(5):632-640
-
Article: WORLD JOURNAL OF UROLOGY. 2021;39(4):1153-1159
-
Article: EUROPEAN UROLOGY FOCUS. 2021;7(2):317-324
-
Article: INTERNATIONAL JOURNAL OF UROLOGY. 2021;28(1):47-52
-
Article: MINERVA UROLOGICA E NEFROLOGICA. 2020;72(6):746-754
-
Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(5):640-647
-
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;20:54-61
-
Article: JOURNAL OF UROLOGY. 2020;204(1):82-90
-
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2020;54(3):220-226
-
Article: FRONTIERS IN PUBLIC HEALTH. 2020;8:571364
-
Article: SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2020;34(1):61-68
-
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2020;38(1):5.e1-5.e8
-
Article: JAMA NETWORK OPEN. 2019;2(11):e1914689
-
Article: EUROPEAN UROLOGY FOCUS. 2019;5(3):389-398
-
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2019;53(1):26-33
-
Article: EUROPEAN UROLOGY. 2018;74(6):816-824
-
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1216-1221
-
Article: EUROPEAN UROLOGY FOCUS. 2018;4(3):351-359
-
Article: ACTA ONCOLOGICA. 2016;55(12):1467-1476
-
Article: BJU INTERNATIONAL. 2016;118(2):205-212
-
Article: EUROPEAN UROLOGY. 2015;68(2):216-225
-
Article: EUROPEAN UROLOGY. 2015;67(4):660-670
-
Article: EUROPEAN UROLOGY. 2015;67(3):559-568
-
Article: JOURNAL OF UROLOGY. 2015;193(1):117-125
-
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2013;47(4):272-281
-
Article: JOURNAL OF UROLOGY. 2012;187(1):196-200
- Show more
All other publications
-
Editorial comment: WORLD JOURNAL OF MENS HEALTH. 2024;42(2):245-255
-
Letter: EUROPEAN UROLOGY ONCOLOGY. 2024;7(1):167-168
-
Letter: JAMA ONCOLOGY. 2022;:1852
-
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7844
-
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7819
-
Letter: EUROPEAN UROLOGY. 2022;81(2):e43
-
Review: CELL COMMUNICATION AND SIGNALING. 2021;19(1):78
-
Review: EUROPEAN UROLOGY OPEN SCIENCE. 2020;20:1-11
-
Review: MINERVA UROLOGICA E NEFROLOGICA. 2019;71(4):301-308
-
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2019;111(7):748
-
Review: MINERVA UROLOGICA E NEFROLOGICA. 2019;71(2):113-120
-
Corrigendum: EUROPEAN UROLOGY. 2017;72(3):e81-e82
Employments
- Affiliated to Research, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2023-2026
- Affiliated to Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2023-2026
Degrees and Education
- Docent, Karolinska Institutet, 2021
- Degree Of Doctor Of Philosophy, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2015
- University Medical Degree, Karolinska Institutet, 2008